| First Author | Sun L | Year | 2018 |
| Journal | Leukemia | Volume | 32 |
| Issue | 1 | Pages | 184-193 |
| PubMed ID | 28555083 | Mgi Jnum | J:254203 |
| Mgi Id | MGI:6110641 | Doi | 10.1038/leu.2017.162 |
| Citation | Sun L, et al. (2018) PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells. Leukemia 32(1):184-193 |
| abstractText | A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARdelta) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARdelta but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARdelta agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARdelta inhibitors. Functional consequences of PPARdelta-mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARdelta modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARdelta antagonists may have therapeutic activity as anti-leukemic signal transduction modulators. |
